GlobalData on MSN5d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatmentThe FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.
This is the first treatment available in this age group for CRSwNP, a chronic inflammatory disease of the upper airway. Approved for adults in June 2019, Dupixent's new indication was granted ...
Zacks.com on MSN4d
Regeneron, SNY Win FDA Approval for a Broader Dupixent LabelREGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...
Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...
The Waltham, Massachusetts-based company has advanced its TSLP inhibitor verekitug into a pair of phase 2 trials in severe ...
The latest research and advances in otolaryngology-head and neck surgery will be presented during the AAO-HNSF 2024 Annual Meeting & OTO EXPOSM in Miami, Florida, September 28 – October 1.
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...
Following Priority Review, Dupixent is now available to patients as young as 12 yearswith inadequately controlled CRSwNP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback